Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strong Quarter 2 boosts Abbott's outlook, while Johnson & Johnson's lacklustre DES (drug eluting stent) sales disappoint

This article was originally published in Clinica

Executive Summary

Abbott surprised analysts this month with second-quarter results that outperformed expectations. Although the company's revenues for the quarter slipped 0.4% from last year's level to $5.5bn, this was $45m more than what analysts had anticipated. Medical product sales grew nearly 18% and were driven by Abbott's vascular division, which benefited from the addition of Guidant's vascular portfolio, including its Xience drug eluting stent (DES), acquired as part of the Boston-Guidant acquisition. Sales of the company's core vascular products soared 50% during the quarter, due to the US launch of its StarClose vascular closure device and the continued momentum of the roll-out of its Xact/Emboshield carotid stent system. The firm says it is planning more product launches for rest of the year, with a full European launch of Xience slated for the end of the third quarter/early fourth quarter, with Zomaxx following closely behind.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052422

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel